Abstract
With the implementation of the DCISionRT (PreludeDx, Laguna Hills, CA) 7-gene biosignature into clinical practice, radiation oncologists are now able to provide patients with DCIS more personalized treatment recommendations regarding pursuing adjuvant radiation treatment or omitting, as the DCISionRT clinicogenomic biosignature is both prognostic for recurrence risk after breast-conserving surgery as well as predictive for benefit of radiation treatment.
Reference5 articles.
1. [1] Vicini FA, Shah CS, Margenthaler J, Dabbs D, Wärnberg F, Weinmann S, Whitworth PW, Czerniecki B, Mann GB, Shivers S, Mittal K, Bremer T. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence (IBR) Rates. International Journal of Radiation Oncology*Biology*Physics DOI 10.1016/j.ijrobp.2023.06.211 [Summary]
2. [2] Dabbs D, Mittal K, Heineman S, Whitworth P, Shah C, Savala J, Shivers SC, Bremer T. Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ. Front Oncol. 2023 May 19;13:1069059. doi: 10.3389/fonc.2023.1069059. PMID: 37274253; PMCID: PMC10236475.
3. [3] Shah C, Bremer T, Cox C, Whitworth P, Patel R, Patel A, Brown E, Gold L, Rock D, Riley L, Kesslering C, Brown S, Gabordi R, Pellicane J, Rabinovich R, Khan S, Templeton S, Majithia L, Willey SC, Wärnberg F, Gerber NK, Shivers S, Vicini FA. The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery. Ann Surg Oncol. 2021 Oct;28(11):5974-5984. doi: 10.1245/s10434-021-09903-1. Epub 2021 Apr 5. Erratum in: Ann Surg Oncol. 2021 May 16;: PMID: 33821346; PMCID: PMC8526470.
4. [4] Vicini FA, Mann GB, Shah C, Weinmann S, Leo MC, Whitworth P, Rabinovitch R, Torres MA, Margenthaler JA, Dabbs D, Savala J, Shivers SC, Mittal K, Wärnberg F, Bremer T. A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):93-102. doi: 10.1016/j.ijrobp.2022.06.072. Epub 2022 Sep 15. PMID: 36115740.
5. [5] Shah C, Vicini F. Adjuvant Radiation Therapy for Ductal Carcinoma In Situ of the Breast: A Clinician's Dilemma. Ann Surg Oncol. 2023 Oct;30(11):6281-6283. doi: 10.1245/s10434-023-13691-1. Epub 2023 Jun 6. PMID: 37280311.